In conclusion, our results reveal a differential expression profile of DNAM-1, TIGIT and TACTILE in NK cells and T cell subsets in AML patients and highlight the importance of the combination of immunotherapeutic strategies aimed at improving lymphocyte activation by blockade of TIGIT checkpoint using anti-TIGIT mAbs in AML patients. The gene discussed is TIGIT; the disease is acute myeloid leukemia.